Healthy-days time equivalents for outcomes of acute rotavirus infections

Vaccine

Volumn 29, Issue 45, 2011, Pages 8086-8093

  Hauber, A Brett ^a   Itzler, Robbin ^b   Johnson, F Reed ^a   Mohamed, Ateesha F ^a   González, Juan Marcos ^a   Cook, John R ^b   Walter, Emmanuel B ^c  

^a RTI INTERNATIONAL   (United States)

^b Duke Clinical Vaccine Unit ^*

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Conjoint analysis; Healthy days equivalents; Rotavirus infections

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; BEHAVIOR CHANGE; COST EFFECTIVENESS ANALYSIS; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; FEVER; GASTROENTERITIS; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; ROTAVIRUS INFECTION; SEIZURE; UNITED STATES; VOMITING; WEIGHT;

ADULT; CHILD, PRESCHOOL; FEMALE; GASTROENTERITIS; HUMANS; MALE; PARENTS; QUALITY-ADJUSTED LIFE YEARS; ROTAVIRUS INFECTIONS; TREATMENT OUTCOME; UNITED STATES;

EID: 80053631135     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.041     Document Type: Article

References (63)

1. Parashar U.D., Alexander J.P., Glass R.I. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006, 50(RR-12):1-16.
2. Velázquez F.R., Matson D.O., Calva J.J., Guerrero L., Morrow A.L., Carter-Campbell S., et al. Rotavirus infection in infants as protection against subsequent infections. N Engl J Med 1996, 335:1022-1028.
3. Staat M.A., Azimi P.H., Berke T., Roberts N., Bernstein D., Ward R. Clinical presentations of rotavirus infection among hospitalized children. Pediatr Infect Dis J 2002, 21:221-227.
4. Payne D.C., Staat M.A., Edwards K.M., Szilagyi P.G., Gentsch J.R., Stockman L.J., et al. Active population based surveillance for severe rotavirus gastroenteritis. Paediatrician 2008, 122:1235-1243.
5. Parashar U.D., Hummelman E.G., Bresee J.S., Miller M.A., Glass R.I. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003, 9(5):565-572.
6. Glass R.I., Lew J.F., Gangarosa R.E., LeBaron C.W., Ho M.S. Estimates of morbidity and mortality rates for diarrheal diseases in American children. J Pediatr 1991, 118:S27-S33.
7. American Academy of Pediatrics: Provisional Committee on Quality Improvement, Subcommittee on Acute Gastroenteritis Practice parameter: management of acute gastroenteritis in young children. Pediatrician 1996, 97:424-436.
8. Ozuah P.O., Avner J.R., Stein R.E.K. Oral rehydration, emergency physicians, and practice patterns: a national survey. Paediatrician 2002, 109:259-261.
9. Mast T.C., Chen P.Y., Lu K.C., Hsu C., Lin H.C., Wen-Chen L., et al. Epidemiology and economic burden of rotavirus gastroenteritis in hospitals and pediatric clinics in Taiwan. Vaccine 2010, 28(17):3008-3013.
10. Mast T.C., DeMuro-Mercon C., Kelly C., Floyd L., Walter E. Impact of rotavirus gastroenteritis on the family. BMC Pediatrics 2009, 9(1):11. [Electronic Resource].
11. Centers for Disease Control: Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory committee on Immunization Practices (ACIP) MMWR 2009, 58(RR2).
12. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354:23-33.
13. Ruiz-Palacios G.M., Pérez-Schael I., Velázquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354:11-22.
14. Vesikari T., Clark H.F., Offitt P.A., Dallas M.J., DiStefano D.J., Goveia M.G., et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety, and immunogenicity in healthy infants. Vaccine 2006, 24:4821-4829.
15. Block S.L., Vesikari T., Goveia M.G., Rivers S.B., Adeyi B.A., Dallas M.J., et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Paediatrician 2007, 119:11-18.
16. Parashar U.D., Glass R. Rotavirus vaccines-early success, remaining questions. N Engl J Med 2009, 360:1063-1065.
17. Bilcke J., Beutels P. Reviewing the cost-effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources. Pharmacoeconomics 2009, 27:1-17.
18. Brisson M., Senecal M., Drolet M., Mansi J.A. Health-related quality of life lost to rotavirus-associated gastroenteritis in children and their parents: a Canadian prospective study. Pediatr Infect Dis J 2010, 29:73-75.
19. Drummond M.F., Sculpher M.J., Torrance G.W., O'Brien B.J., Stoddart G.L. Methods for the economic evaluation of health care programmes 2005, Oxford University Press, Oxford. Third edition.
20. Murray C.J.L., Acharya A.K. Understanding DALYs. J Health Econ 1997, 16:703-730.
21. Murray C.J.L. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ 1994, 72(3):429-445.
22. Pliskin J.S., Shepard D.S., Weinstien M.C. Utility functions for life years and health status. Oper Res 1980, 28:206-224.
23. Weinstein M.C., Fineberg H.V. Clinical decision analysis 1980, W.B. Saunders, Philadelphia.
24. Mehrez A., Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making 1989, 9(2):142-149.
25. Anand S., Hanson K. Disability-adjusted life years: a critical review. J Health Econ 1997, 16:685-702.
26. Smth M.D., Drummond M., Brixner D. Moving the QALY forward: rationale for change. Value in Health 2009, 12(Suppl. 1):S1-S4.
27. Griebsch I., Coast J., Brown J. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Paediatrician 2005, e600-e614.
28. Sénécal M., Brisson M., Lebel M.H., Yaremko J., Wong R., Gallant L.A., et al. Measuring the Impact of rotavirus acute gastroenteritis episodes (MIRAGE): a prospective community-based study. Can J Infect Dis Med Microbiol 2008, 19(6):397-404.
29. Martin A., Batty A., Roberts J.A., Standaert B. Cost-effectiveness of infant vaccination with RI4414 (Rotarix™) in the UK. Vaccine 2008, 27(33):4520-4528.
30. Goossens L.M.A., Standaert B., Hartwig N., Hovels A.M., Al M.J. The cost-utility of rotavirus vaccination with Rotarix™ (RIX4414) in the Netherlands. Vaccine 2008, 26(8):1118-1127.
31. Grange A., Bekker H., Noyes J., Langley P. Adequacy of health-related quality of life measures in children under 5 years old: systematic review. J Adv Nurs 2007, 59(3):197-220.
32. Mehrez A., Gafni A. The healthy-years equivalents: how to measure them using the standard gamble approach. Med Decis Making 1991, 11(2):140-146.
33. Hauber A.B. Healthy-years equivalent: wounded but not yet dead. Exp Rev Pharmacoecon Outcomes Res 2009, 9(3):265-269.
34. Johnson F.R., Hauber A.B., Özdemir S. Using conjoint analysis to estimate healthy-year equivalents for acute conditions: an application to vasomotor symptoms. Value Health 2009, 12(1):146-152.
35. Bridges J.F.P., Kinter E.T., Kidane L., Heinzen R.R., McCormick C. Things are looking up since we started listening to patients: trends in the application of conjoint analysis in health 1982-2007. Patient 2008, 1(4):273-282.
36. Louviere J., Swait J., Hensher D. Introduction to stated preference models and methods. Stated choice methods: analysis and application 2000, Cambridge University Press, Cambridge, UK, pp. 20-33.
37. Gan T.J., Lubarsky D.A., Flood E.M., Thanh T., Mauskopf J., Mayne T., et al. Patient preferences for acute pain treatment. Br J Anaesth 2004, 92(5):681-688.
38. Johnson F.R., Banzhaf M., Desvousges W. Willingness to pay for improved respiratory and cardiovascular health: a multiple-format stated-preference approach. Health Econ 2000, 9:295-317.
39. Ryan M., McIntosh E., Shackley P. Methodological issues in the application of conjoint analysis in health care. Health Econ 1998, 7:373-378.
40. Bryan S., Martin B., Robert S., Alison G. Magnetic resonance imaging for the investigation of knee injuries: an investigation of preferences. Health Econ 1998, 7:595-603.
41. Ryan M., Gerard K. Discrete choice experiments. Assessing quality of life in clinical trials: methods and practice: second edition 2005, 431-445. Oxford University Press, Oxford, UK. P. Fayers, R. Hays (Eds.).
42. Givon-Lavi N., Greenberg D., Dagan R. Comparison between two severity scoring scales commonly used in the evaluation of rotavirus gastroenteritis in children. Vaccine 2008, 26(46):5798-5801.
43. Clark H.F., Bonan F.E., Bell L.M., Modesto K., Gouvea V., Plotkin S.A. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. JID 1988, 158:570-578.
44. Ruuska T., Vesikari T. Rotavirus disease in finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand JID 1990, 22:259-267.
45. World Health Organization. Diarrhoeal Disease Control Programme. The treatment of diarrhoea: a manual for physicians and other senior health workers.1995 WHO/CDR/95.3.
46. Gorelick M.H., Shaw K.N., Murphy K.O. Validity and reliability of clinical signs in the diagnosis of dehydration in children. Paediatrician 1997, 99(5):E6.
47. Lynch M., Shieh W.J., Tatti K., Gentsch J.R., Ferebee-Harris T., Jiang B., et al. The pathology of rotavirus-associated deaths using new molecular diagnostics. Clin Infect Dis 2003, 37(10):1327-1333.
48. Huber J., Zwerina K. The importance of utility balance in efficient choice designs. J Market Res 1996, 33:307-317.
49. Kanninen B. Optimal design for multinomial choice experiments. J Market Res 2002, 39:214-227.
50. Zwerina K., Huber J., Kuhfeld W. A general method for constructing efficient choice designs. Durham: fuqua school of business 1996, Duke University, Available at: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.31.9438&rep=rep1&type=pdf (accessed 09.03.09).
51. Dey A. Orthogonal fractional factorial designs 1985, Halstead Press, New York.
52. Kuhfeld W., Tobias F., Garratt M. Efficient experimental design with marketing research applications. J Market Res 1994, 31:545-557.
53. Petrou S., McIntosh E. Measuring the benefits of growth hormone therapy in children: a role for preference-based approaches?. Arch Dis Child 2008, 93:95-97.
54. Aspinall P., Johnson Z., Azuara-Blanco A., Montarzino A., Brice R., Vickers A. Evaluation of quality of life and priorities of patients with glaucoma. Invest Ophthalmol Vis Sci 2008, 49(5):1907-1915.
55. Hollinghurst S., Shaw A., Thompson E. Capturing the value of complementary and alternative medicine: including patient preferences in economic evaluation. Complement Ther Med 2008, 16:47-51.
56. Gyrd-Hansen D., Sogaard J. Analysing public preferences for cancer screening programmes. Health Econ 2001, 10:617-634.
57. Schmier J., Palmer C., Flood E., Gourlay G. Utility assessments of opioid treatment for chronic pain. Pain Med 2002, 3(3):218-230.
58. McIntosh E., Donaldson C., Ryan M. Recent advances in the methods of cost benefit analysis in health care: matching the art to the science. Pharmacoeconomics 1999, 15(4):357-367.
59. McIntosh E. Using discrete choice experiments within a cost benefit analysis framework: some considerations. Pharmacoeconomics 2006, 24(9):855-868.
60. Bishai D., Brice P., Girod I., Saleh A., Ehreth J. Conjoint analysis of French and German parents' willingness to pay for meningococcal vaccine. Pharmacoeconomics 2007, 25(2):143-154.
61. Two R., Verjee-Lorenz A., Clayson D., Dalal M., Grotzinger K., Younossi Z.M. A methodology for successfully producing global translations of patient reported outcome measures for use in multiple countries. Value Health 2010, 13(1):128-131.
62. Wild D., Eremenco J., Mear I., Martin M., Houchin C., Gawlicki M., et al. Multinational trials-recommendations on the translations required, approaches to using the same language in different countries and the approaches to support pooling the data: the ISPOR patient-reported outcomes translation and linguistic validation good research practices task force report. Value Health 2009, 12(4):430-440.
63. Atkinson M.J., Lohs J., Kuhagen I., Kaufman J., Bhaidani S. A promising method for identifying cross-cultural differences in patient perspective: the use of internet-based focus groups for content validation of new patient reported outcome assessments. Health Qual Life Outcomes 2006, 4(64):1-14. [Electronic Resource].